Mar 12, 2022 04:00 PM

Weekly Must-Read: China Meheco Confirms Pfizer Talks on Selling Paxlovid in China

Pfizer’s Covid-19 pill Paxlovid lowered hospitalization and death rates by 89% in patients who took it within five days of the onset of illness.

The Caixin Must-Read newsletter brings you the best of our coverage over the past week, handpicked by our editors.

State-owned drugmaker signs 2022 supply contract to commercialize Paxlovid as the first foreign treatment approved in China

You've accessed an article available only to subscribers

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

00:00

00:00/00:00

3: Chart of the Day: CATL Leads Chinese Clean-Tech Firms in Overseas Investments

5: Hong Kong Launches Task Force to Shepherd Chinese Mainland Firms Overseas